Retatrutide vs Tirzepatide: What the Evidence Shows Right Now

The biggest misconception: retatrutide is not a step beyond Mounjaro you can take yet

It is completely understandable to feel frustrated. You have probably read breathless coverage of retatrutide trial results and wondered whether waiting for it makes sense. The reality is that retatrutide has not received MHRA approval, has no UK marketing authorisation, and is not available from any legitimate UK pharmacy. Phase 2 trial data published in the New England Journal of Medicine showed impressive average weight reductions (up to around 24% at the highest dose over 48 weeks) but phase 2 trials involve hundreds of participants under tightly controlled conditions, not the thousands of real-world patients needed to underpin a full licensing submission.

Tirzepatide, by contrast, has completed a large-scale clinical programme. Mounjaro's phase 3 SURMOUNT-1 trial randomised 2,539 adults with obesity and reported average body-weight reductions of around 20–21% at 15mg over 72 weeks. That evidence base supported the NICE recommendation and the MHRA licence. If you want to understand how retatrutide compares with Mounjaro across those key measures, it is worth reading the detail carefully, because treating them as equivalent options overstates where retatrutide actually is.

If you are wondering whether to wait, our prescribers are asked this question regularly. The honest answer is that no UK timeline for retatrutide licensing exists at the time of writing, and effective, well-studied treatment is available today.

How the mechanisms and trial data differ

Retatrutide targets three receptors: GIP, GLP-1, and glucagon. Tirzepatide targets two: GIP and GLP-1. In theory, adding glucagon agonism could amplify energy expenditure alongside appetite reduction — and that is the scientific rationale behind retatrutide's development. Phase 2 results were striking enough to move the programme to phase 3. For a closer look at how reta stacks up against tirzepatide on mechanism and trial outcomes, the differences in receptor action and tolerability data are worth examining, since the glucagon pathway also carries additional considerations around heart rate that longer trials will need to characterise fully.

The table below summarises the key factual differences based on current evidence.

You can read more about how tirzepatide relates to the Mounjaro brand if that distinction is useful context.

What being unlicensed means in practice for UK patients

The NHS tirzepatide page on nhs.uk covers Mounjaro's approved use, known side effects, and the clinical framework around it, because it has been through a full regulatory review. No equivalent exists for retatrutide. There is no Patient Information Leaflet, no approved dosing schedule, no GPhC-registered pharmacy that can legally dispense it, and no prescriber in the UK who can lawfully prescribe it for weight management. If you come across sellers claiming to offer retatrutide pens, the MHRA's counterfeit warnings are directly relevant, unlicensed medicines sold online carry serious risks, and the MHRA has conducted significant enforcement action against illegal weight-loss medicine supply. Any question about switching from tirzepatide to retatrutide is, for now, a question about the future rather than a practical choice.

The cost of Mounjaro and what private treatment includes is a reasonable thing to look at once you have established that it is the medicine you are actually eligible for. Those wondering whether retatrutide is better than Mounjaro will find that the question cannot be answered definitively yet, given how different the evidence bases are at this stage.

Which should you choose?

The clinical answer is straightforward: only one of these medicines can be prescribed to you in the UK today. Tirzepatide has the evidence base, the regulatory sign-off, and the clinical infrastructure around it. Our clinical team assesses every consultation personally, and the question of whether Mounjaro is clinically suitable for you depends on your BMI, your health history, and any medicines you already take, not on a self-comparison between two options, only one of which is available. Retatrutide may well reach the UK at some point. When it does, the evidence will look different from what a 48-week phase 2 trial can show. Until then, check your eligibility for treatment with our prescribers and make a decision based on what is real and accessible right now. Which medicine suits you is a clinical decision our prescribers make with you, once they have seen the full picture.